Home › Kanser sa Suso › Michigan › Detroit
Pag-aaral pangklinika para sa Kanser sa Suso sa Detroit, MI
Isang pag-aaral para sa Kanser sa Suso ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Detroit. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
The Vanguard Study: Testing a New Way to Screen for Cancer
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Henry Ford Hospital, Detroit
- Henry Ford Medical Center - Detroit Northwest, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Nagre-recruitPhase 2
- Henry Ford Hospital, Detroit
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Nagre-recruitPhase 3
- Henry Ford Health ( Site 0002), Detroit
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
Nagre-recruitPhase 3
- Research Site, Detroit
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Nagre-recruit
- Karmanos Cancer Center - Wayne State University, Detroit
A Study of LY4257496 in Participants With Cancer (OMNIRAY)
Nagre-recruitPhase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
Nagre-recruitPhase 1
- Barbara Ann Karmanos Cancer Institute, Detroit
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Nagre-recruitPhase 3
- Henry Ford Hospital, Detroit
A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
- Brigitte Harris Cancer Pavilion BHCP, Detroit
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Nagre-recruitPhase 3
- Karmanos Cancer Center, Detroit
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Nagre-recruitPhase 1
- Karmanos Cancer Institiute, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Nagre-recruitPhase 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Nagre-recruitPhase 1/2
- Henry Ford Hospital, Detroit
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
Nagre-recruitPhase 1/2
- Wayne State University - Barbara Ann Karmanos Cancer Institute, Detroit
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Nagre-recruitPhase 3
- Henry Ford Health System, Detroit
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Nagre-recruitPhase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Ph II Study of the TheraBionic P1 Device in Subjects With Hormone Positive Breast Cancer
Nagre-recruit
- Karmanos Cancer Institute, Detroit
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
Nagre-recruitPhase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Nagre-recruitPhase 2/3
- Henry Ford Cancer- Detroit (Brigitte Harris Cancer Pavilion), Detroit
E-Mindfulness Approaches for Living After Breast Cancer
Nagre-recruitPhase 3
- Henry Ford Hospital, Detroit
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
- Henry Ford Health, Detroit
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Nagre-recruitPhase 1/2
- Henry Ford Health Hospital, Detroit
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Nagre-recruitPhase 1/2
- Henry Ford Hospital, Detroit
Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2)
Nagre-recruitPhase 3
- Henry Ford Health System, Detroit
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Nagre-recruitPhase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study of the TheraBionic P1 Device in Breast Cancer
Nagre-recruit
- Karmanos Cancer Institute, Detroit
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Nagre-recruitPhase 1/2
- Henry Ford Health System, Detroit
Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
Nagre-recruitPhase 1/2
- Karmanos Cancer Institute, Detroit
F-Tryptophan PET/CT in Human Cancers
Nagre-recruitPhase 1
- Karmanos Cancer Institute, Detroit
S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity
Nagre-recruitPhase 3
- Wayne State University/Karmanos Cancer Institute, Detroit
- Henry Ford Hospital, Detroit
A Study of Disappearing Markers for Daily Radiation Treatment Delivery for Breast Cancer Patients.
Nagre-recruit
- Karmanos Cancer Institute, Detroit
Pag-aaral para sa Kanser sa Suso sa ibang lungsod
- New York City, NY136 pag-aaral
- Houston, TX126 pag-aaral
- Boston, MA112 pag-aaral
- Nashville, TN81 pag-aaral
- Los Angeles, CA73 pag-aaral
- Edison, NJ68 pag-aaral
- St. Louis, MO64 pag-aaral
- Queens, NY64 pag-aaral
- Durham, NC64 pag-aaral
- Chicago, IL59 pag-aaral
- Philadelphia, PA56 pag-aaral
- Dallas, TX55 pag-aaral
Iba pang pag-aaral sa Detroit
- Non-Small Cell Lung Cancer44 pag-aaral
- Kanser (lahat ng uri)29 pag-aaral
- Colorectal Cancer26 pag-aaral
- Kanser sa Ovary26 pag-aaral
- Metastatic Cancer24 pag-aaral
- Kanser sa Prostate22 pag-aaral
- Kanser ng Endometrium21 pag-aaral
- Kanser sa Baga20 pag-aaral
- Multiple Myeloma19 pag-aaral
- Kanser sa Tiyan16 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg15 pag-aaral
- Acute Myeloid Leukemia14 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.